Ipamorelin is a synthetic growth hormone-releasing peptide (GHRP). Individuals use it for anti-aging purposes, sleep enhancement, injury recovery, and to improve body composition.
Ipamorelin is a pentapeptide, which means that it contains five amino acids. Ipamorelin is a ghrelin mimetic with growth hormone (GH) releasing activity. As such, it mimics ghrelin, which is a peptide hormone that stimulates feeding and appetite behavior. Ipamorelin binds the ghrelin receptor, allowing for the release of GH from the pituitary gland and increased plasma GH levels (1).
A noteworthy part of ipamorelin is that it provides selective GH release, meaning it stimulates GH release without affecting other hormones like prolactin, cortisol, or adrenocorticotropic hormone (ACTH). As such, it may lead to less unwanted effects. Additionally, it doesn’t stimulate appetite to the same extent as ghrelin (2).
There is limited research characterizing ipamorelin in humans, but one study executed pharmacokinetic (PK) and pharmacodynamic (PD) modeling of ipamorelin in healthy volunteers. The study showed that ipamorelin induced dose-dependent growth hormone release (3). The only other study in humans was a phase II trial focusing on ipamorelin use in GI recovery after surgery (4).
However, animal models show some positive preliminary results. Animal models demonstrate consistent findings that ipamorelin stimulates GH release via the ghrelin receptor pathways with minimal off-target hormonal effects (5).
Early-phase trials, including pharmacokinetic and Phase II studies, have been conducted in humans. However, because there were not strong efficacy outcomes, it seems that further development in humans has been largely discontinued. That being said, the majority of the evidence comes from animal models that show robust GH stimulation and metabolic effects, meaning that ipamorelin use is largely experimental at this phase.
In terms of regulation, ipamorelin is not approved for any indication by the US Food and Drug Administration (FDA). It is available online through peptide vendors and some medical clinics, however, it is not an FDA-approved bulk substance for compounding.
Finally, as ipamorelin is not FDA-approved, it does not abide by the typical standards for safety, efficacy, and quality. It carries a risk for mislabeling and contamination as such.
There are several potential safety concerns to be aware of with ipamorelin due to its close link to growth hormone and IGF-1. Increased GH and IGF-1 levels are linked to downstream effects like blood sugar dysregulation, fluid retention, and potential cancer risk. It is difficult to fully characterize these risks due to the lack of late-phase human studies with ipamorelin.
In summary, ipamorelin is a biologically active substance that has demonstrated effects in the GH and IGF pathways. While it shows some promise in animals, its effects have yet to be substantiated in humans via well-controlled clinical trials. It is not regulated by the FDA and thus does not have the same stringent oversight as other drugs, leading to potential quality concerns.
The information provided in this article is for educational purposes only and is not intended as medical advice. Many peptides are not FDA-approved for human use outside of limited clinical contexts. These compounds are often obtained through unregulated sources that lack quality control. Studies suggest 30–65% of products may be contaminated or mislabeled, with risks including endotoxins, heavy metals, and incorrect sequences. At Weight Loss & Vitality, we focus on evidence-based, medically supervised therapies.
As of April 21, 2026, regulatory status for many peptides remains under review and may change as additional data and guidance become available.
The science behind peptides continues to evolve, highlighting the need for responsible and informed use. At Weight Loss & Vitality, our peptide therapy programs are grounded in clinical experience and evidence-based care.
References
https://peptide.co/research/ipamorelin/
